
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES191
This study compared gemfibrozil 1,200 mg and a matched placebo in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT) and included a subgroup diabetic, N=627.299
This study considered major CV events and identified in the diabetes group a significant reduction in the risk of major CV events of 32%, of CHD death 41%, and of stroke 40%, compared with placebo.
The lipid level analysis was not analysed by diabetic subgroup. Level 1+

[@Rubins_2002]

